Development and validation of a UPLC-MS method for determination of atazanavir sulfate by the “analytical quality by design” approach
Authors:
Open Access
- 1 November 2019
- journal article
- research article
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 70 (1) , 17-33
Abstract
A UPLC-MS method for the estimation of atazanavir sulfate was developed using the “analytical quality by design” approach. The critical chromatographic quality attributes identified were retention time, theoretical plates and peak tailing. The critical method parameters established were percent of organic modifier, flow rate and injection volume. Optimization performed using Box-Behnken Design (BBD) established 10 % organic modifier, 0.4 mL min −1 flow rate and 6-µL injection volume as the optimum method conditions. Atazanavir sulfate eluted at 5.19 min without any interference. Method validation followed international guidelines. The method has proven linearity in the range of 10–90 µg mL −1 . Recovery was between 100.2–101.0 % and precision within the accepted limits (RSD 0.2–0.7 %). LOD and LOQ were 2.68 and 8.14 µg mL −1 , resp. Stress testing stability studies showed atazanavir sulfate to degrade under acidic and basic conditions. The suggested technique is simple, rapid and sustainable. It is, therefore, suggested for routine analysis of atazanavir sulfate.Keywords
This publication has 27 references indexed in Scilit:
- Stability indicating RP-HPLC method for the determination of Atazanavir sulphate in bulk and dosage formDrug Invention Today, 2013
- Pharmacokinetic-Pharmacodynamic Modeling of Unboosted Atazanavir in a Cohort of Stable HIV-Infected PatientsAntimicrobial Agents and Chemotherapy, 2013
- Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfateJournal of Pharmaceutical and Biomedical Analysis, 2011
- Atazanavir Pharmacokinetics With and Without Tenofovir During PregnancyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Validation of a rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) assay for the simultaneous determination of existing and new antiretroviral compoundsJournal of Chromatography B, 2010
- Tapping into combination pills for HIVNature Reviews Drug Discovery, 2009
- Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detectionJournal of Pharmaceutical and Biomedical Analysis, 2006
- Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extractionJournal of Chromatography B, 2004
- Infectious diseasesNature Reviews Drug Discovery, 2004
- Atazanavir sulphateNature Reviews Drug Discovery, 2003